Buscar

Estamos realizando la búsqueda. Por favor, espere...

 Detalle_Publicacion

The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases

Abstract: Interleukin-17 family (IL-17s) comprises six structurally related members (IL-17A to IL-17F); sequence homology is highest between IL-17A and IL-17F, displaying certain overlapping functions. In general, IL-17A and IL-17F play important roles in chronic inflammation and autoimmunity, controlling bacterial and fungal infections, and signaling mainly through activation of the nuclear factor-kappa B (NF-?B) pathway. The role of IL-17A and IL-17F has been established in chronic immune-mediated inflammatory diseases (IMIDs), such as psoriasis (PsO), psoriatic arthritis (PsA), axial spondylarthritis (axSpA), hidradenitis suppurativa (HS), inflammatory bowel disease (IBD), multiple sclerosis (MS), and asthma. CD4+ helper T cells (Th17) activated by IL-23 are well-studied sources of IL-17A and IL-17F. However, other cellular subtypes can also produce IL-17A and IL-17F, including gamma delta (??) T cells, alpha beta (??) T cells, type 3 innate lymphoid cells (ILC3), natural killer T cells (NKT), or mucosal associated invariant T cells (MAIT). Interestingly, the production of IL-17A and IL-17F by innate and innate-like lymphocytes can take place in an IL-23 independent manner in addition to IL-23 classical pathway. This would explain the limitations of the inhibition of IL-23 in the treatment of patients with certain rheumatic immune-mediated conditions such as axSpA. Despite their coincident functions, IL-17A and IL-17F contribute independently to chronic tissue inflammation having somehow non-redundant roles. Although IL-17A has been more widely studied, both IL-17A and IL-17F are overexpressed in PsO, PsA, axSpA and HS. Therefore, dual inhibition of IL-17A and IL-17F could provide better outcomes than IL-23 or IL-17A blockade.

Otras publicaciones de la misma revista o congreso con autores/as de la Universidad de Cantabria

 Fuente: Frontiers in Immunology, 2023, 14, 1191782 - (CORRIGENDUM), 2023, 14, 1332177

Editorial: Frontiers Research Foundation

 Año de publicación: 2023

Nº de páginas: 14

Tipo de publicación: Artículo de Revista

 DOI: 10.3389/fimmu.2023.1191782

ISSN: 1664-3224

Url de la publicación: https://doi.org/10.3389/fimmu.2023.1191782

Autores/as

NAVARRO-COMPÁN, VICTORIA

PUIG, LULIS

VIDAL, SILVIA

RAMÍREZ, JULIO

LLAMAS-VELASCO, MAR

FERNÁNDEZ-CARBALLIDO, CRISTINA

ALMODÓVAR, RAQUEL

PINTO, JOSÉ ANTONIO

GALÍNEZ-AGUIRREGOIKOA, EVA

ZARCO, PEDRO

JOVEN, BEATRIZ

GRATACÓS, JORDI

JUANOLA, XAVIER

ARIAS-SANTIAGO, SALVADOR

SANZ SANZ, JESÚS

QUEIRO, RUBÉN

CAÑETE, JUAND D.